resmed stock (RMD) Guide

ResMed Stock (RMD)

As a concise lead: resmed stock refers to publicly traded shares of ResMed, Inc., a San Diego–based medical device and cloud‑connected health company traded under the ticker RMD. ResMed is widely regarded as a large‑cap medical devices and digital‑health equity. This article covers listing details, share structure, commonly used market and financial metrics, historical performance, company fundamentals, dividend policy, ownership, analyst coverage, typical news catalysts, risk factors, valuation approaches, trading practicalities (including a note on using Bitget for access), regulatory matters, related instruments and primary data sources. Readers will gain a practical reference for researching resmed stock and pointers for where to verify time‑sensitive figures.

If you want quick access: start at the "Ticker, listings and share structure" and "Market data and key metrics" sections for trading basics; read "Financial results and fundamentals" and "Risks" for investment context; use the "Historical resources and data sources" section to find live data.

Company overview

ResMed designs, manufactures and sells devices and cloud‑connected software for the diagnosis, treatment and management of sleep‑disordered breathing (including obstructive sleep apnea), chronic obstructive pulmonary disease (COPD) and other chronic respiratory conditions. The company operates mainly across two reporting segments: Sleep & Respiratory Care (devices, masks, accessories, ventilators) and Residential Care Software (cloud platforms, remote patient monitoring, care‑management software for home healthcare providers and payors).

Customers include patients (through provider channels), hospitals and clinics, sleep and respiratory specialists, home‑health providers, and institutional purchasers such as health systems and insurers in many countries. ResMed has an extensive global footprint covering North America, Europe, Asia Pacific and other regions through its direct operations, distributors and partnerships.

Ticker, listings and share structure

• Primary ticker: NYSE: RMD.
• Secondary trading instrument: CHESS Depositary Interests traded on the Australian Securities Exchange (ASX) under the symbol RMD (via CDIs) to facilitate local investor access in Australia while the company is incorporated and headquartered in the United States.
• Share classes: ResMed historically trades a single publicly listed class of common stock; there are no publicly traded dual‑class shares reported in standard filings.
• Shares outstanding and float: total shares outstanding and public float change with buybacks and issuance. As an example timestamp, as of 2024‑06‑30, major financial data providers reported total shares outstanding in the low hundreds of millions range and a public float representing the majority of that figure. For the most accurate current numbers, consult ResMed's most recent 10‑Q/10‑K and market data feeds.
• Headquarters and identifiers: ResMed, Inc. is headquartered in San Diego, California; its CIK and SEC identifiers and other corporate IDs appear in filings on the company investor relations site and SEC EDGAR.

Market data and key metrics

Investors commonly monitor the following market metrics for resmed stock:

• Market capitalization: reflects shares outstanding × market price. As of 2024‑06‑30, financial data services reported a market cap in the low tens of billions of US dollars (example figure: ~36.5 billion USD). Market cap is time‑sensitive and fluctuates with price.
• Price‑to‑earnings (P/E) and forward P/E: trailing and forward P/E ratios vary with reported earnings and analyst estimates. Typical trailing P/E ranges observed for ResMed in recent years have often fallen in the broad mid‑teens to mid‑thirties range depending on market conditions and company earnings; forward P/E typically reflects analyst growth expectations and can be materially lower or higher.
• Earnings per share (EPS): trailing EPS and consensus forward EPS are published by data providers and in company releases. For example, trailing twelve‑month EPS as of mid‑2024 was reported in single‑digit US dollar amounts (verify for current data).
• Dividend and yield: ResMed has paid regular cash dividends. As of 2024‑06‑30, the annual dividend totaled a low single‑digit US dollar amount per share, producing a modest yield below 1% in many periods; yields change with market price.
• Beta: a measure of volatility vs. the market; ResMed's beta has commonly been below or around 1.0, indicating market‑like or somewhat lower volatility.
• Average daily volume: liquidity measures like 30‑ or 90‑day average daily share volume are reported by market data vendors; mid‑2024 figures commonly indicated average volumes measured in the hundreds of thousands to low millions of shares traded per day.
• 52‑week high / low: time‑sensitive high/low prices reported by financial sites; as of mid‑2024, a representative 52‑week high and low span would typically reflect recent peaks and troughs in the market cycle (for exact levels consult a market data feed).

Note: "As of" dates matter. All numeric values above are examples reported by standard market data providers and should be cross‑checked against live sources when making decisions. Data providers include the company's investor relations pages, major financial portals and SEC filings.

Historical stock performance

ResMed has displayed long‑term growth characteristics typical of established medical device companies that combine product sales with subscription‑style cloud services. Over multiple years, resmed stock has reflected both organic product growth (device and mask sales) and increasing recurring revenue from its cloud platforms and software offerings. Notable patterns in historical price performance include multi‑year appreciation driven by revenue growth, periodic sell‑offs around macroeconomic uncertainty, and sharp intraday moves around earnings announcements.

Historical highs and lows: markets report adjusted historical prices (taking into account stock splits and dividends) that are available from major data vendors. For precise historical charts and adjusted series, consult historical price pages provided by market data publishers.

Stock splits and dividends: ResMed's public history of stock splits is limited in recent decades; dividends have been paid regularly and in growing or stable amounts in many years. For a detailed dividend history and any split records, consult the company’s dividend notices and official filings.

Where to view historical price charts and adjusted data: financial sites such as the company investor relations pages and major market data vendors provide downloadable historical price series, total return charts and adjusted close figures.

Financial results and fundamentals

Key financial drivers for resmed stock are rooted in the company’s revenue mix, margins, and the growth of higher‑margin software and services.

• Revenue trends: revenue primarily derives from device and consumable sales (masks, accessories) and from subscription/licensing and services revenue tied to connected devices and care‑management platforms. Over recent reporting periods, ResMed has emphasized growth in recurring software revenue as a strategic priority.
• Profitability: gross margins on devices and consumables and operating margins on software differ; software and services typically carry higher gross margins and recurring cash flows that can support valuation premiums. Net income and margins fluctuate with product mix, investment in R&D and sales/marketing, and currency impacts from global operations.
• Segment contributions: ResMed’s Sleep & Respiratory Care segment historically accounts for the majority of revenue, while Residential Care Software (or similar named segments) contributes a smaller but faster‑growing share with higher recurring characteristics.
• Earnings cadence: ResMed reports quarterly results with management commentary and guidance. Key items that investors track include revenue growth, recurring revenue trends, installed base metrics, margins, free cash flow, and management's guidance for future quarters.

Official filings and releases: for authoritative figures, consult ResMed’s quarterly (10‑Q) and annual (10‑K) reports, proxy statements, and earnings releases available through the company’s investor relations site and SEC EDGAR filings.

Dividend policy and shareholder returns

ResMed maintains a dividend policy of paying regular cash dividends to shareholders. Dividend frequency is typically quarterly, and ex‑dividend, record and payment dates are announced in company releases.

• Dividend role in total return: dividends have been a modest component of total shareholder return compared with capital appreciation driven by revenue growth and multiple expansion. For long‑term investors, the combination of modest cash yield plus growth in earnings and buybacks (if any) shapes total return.
• Tracking dividends: consult the company’s investor relations announcements and market data services for the most recent dividend per share, ex‑dividend dates and yield calculations.

Ownership and institutional interest

ResMed’s ownership profile typically includes a dominant share of institutional investors (mutual funds, pension funds, asset managers) and a smaller portion of insider holdings (executive officers and directors). Major shareholders visible in filings and market screens often include large institutional asset managers and index funds.

• Institutional ownership: high institutional ownership is common in large‑cap medical device names and can contribute to relatively stable shareholder bases; ownership percentages change with quarter‑end filings.
• Insider holdings: company executives and board members hold shares and options; their aggregated holdings appear in proxy statements.
• Short interest: reported short interest as a percentage of float is monitored as an indicator of bearish sentiment or potential short‑squeeze dynamics. Short interest data are reported periodically and change over time.

For the latest concentration statistics and major holders, reference quarter‑end 13F filings and the company’s proxy materials.

Analyst coverage and consensus

ResMed typically receives coverage from a range of sell‑side analysts at investment banks and independent research firms. Analyst reports provide model‑based forecasts, target prices and buy/hold/sell recommendations. Commonly cited elements in analyst coverage include:

• Consensus estimates: aggregated revenue and EPS forecasts over the next 12 months and following fiscal years.
• Rating distribution: the proportion of buy/hold/sell ratings, which may shift over time.
• Target price ranges: implied upside/downside based on analysts’ financial models.

Analyst opinions are periodically updated and can influence short‑term market movements around earnings releases and guidance. Remember that analyst views vary and are not guaranteed predictors of future performance.

Recent developments and news catalysts

Categories of news that commonly move resmed stock include the following:

• Quarterly earnings results and forward guidance revisions.
• Regulatory approvals and clearances (e.g., FDA 510(k) clearances or similar international approvals) for new devices or software modules.
• Product launches and major commercial partnerships that expand distribution or reimbursement coverage.
• Acquisitions or divestitures that alter the company’s product mix or recurring revenue profile.
• Investor conferences, management presentations and analyst days where the company updates strategy or long‑term targets.

As an example of dated reporting: As of 2024‑06‑30, according to the company’s investor relations materials, ResMed reported quarterly results that emphasized continued growth in cloud‑connected subscriptions and ongoing investments in residential care software. For the very latest news and specific items (approval dates, acquisition terms, earnings dates), consult ResMed’s investor relations announcements and financial news outlets.

As of 2026‑01‑27, according to public investor resources, readers should verify any subsequent FDA actions, product announcements or M&A activity directly on the company IR page and regulatory databases for up‑to‑date confirmation.

Risks and factors affecting stock performance

Key risk categories that materially affect resmed stock include:

• Regulatory and reimbursement risk: medical devices and connected health solutions operate in regulated environments. Changes in regulatory requirements or unfavorable reimbursement decisions can reduce adoption or sales.
• Competition: other medical device and digital‑health firms compete on device performance, price, distribution and software capabilities. Competitive innovation can pressure pricing and market share.
• Macro and supply‑chain exposure: macroeconomic slowdowns, currency fluctuation, supply‑chain disruptions and component shortages may impact production and delivery timelines.
• Dependence on product adoption and consumables: a portion of ResMed’s cash flow depends on recurring purchases of masks and accessories; changes in patient behavior or reimbursement for consumables alter revenue dynamics.
• Clinical data and policy: clinical trial outcomes, changes in clinical practice guidelines, or payer policy decisions can influence long‑term adoption of devices and digital therapies.
• Litigation and legal risk: product liability or intellectual property litigation is a standard risk for medical‑device firms.

Investors should consider how these risks interact with company strategy and valuation.

Valuation and investment considerations

Common valuation approaches used on resmed stock include:

• Price‑to‑earnings (P/E): compares price to trailing or forward EPS. Useful for relative valuation vs. peers but sensitive to near‑term earnings variability.
• Enterprise value / EBITDA (EV/EBITDA): helps compare companies with different capital structures, useful for capital‑intensive device makers.
• Discounted cash flow (DCF): models future free cash flows to estimate intrinsic value under explicit growth and margin assumptions.

Qualitative considerations include:

• Recurring revenue mix: growing subscription and cloud revenues can justify higher multiples due to predictability and margin lift.
• Installed base and accessories: an extensive installed base drives mask and accessory sales and maintenance revenue.
• Demographics and addressable market: aging populations and increased diagnosis of sleep apnea and chronic respiratory disease support long‑term demand.
• Execution risk: margin expansion and successful product rollouts depend on effective global commercialization and supply operations.

Valuation outcomes depend heavily on the choice of growth and margin assumptions. This guide does not provide investment advice; readers should combine up‑to‑date market data with their own analysis.

Trading considerations and how to buy

• Where to trade: resmed stock is available through major brokers that provide access to NYSE‑listed US equities and, for Australian investors, through CHESS Depositary Interests on the ASX. For investors using crypto or Web3 rails, Bitget provides access to markets and custody tools—if you prefer a single platform ecosystem, consider Bitget and Bitget Wallet for secure holdings and trading operations (note: verify instrument availability and local regulations on Bitget for equities or related tokenized products).
• Liquidity and order types: RMD is generally liquid on the NYSE; use limit orders to control execution price in volatile periods. Time‑sensitive traders may use market orders during regular hours but accept potential slippage.
• Options: exchange‑traded options on RMD may be available for hedging or income strategies; check option chain availability with your broker.
• Differences between NYSE shares and ASX CDIs: NYSE shares are U.S. listed ordinary shares; ASX CHESS Depositary Interests allow Australian investors local custody and settlement while representing the U.S. shares. Differences may include settlement timelines, local taxation considerations and currency exposure. Consult your broker and tax advisor.

Regulatory and legal matters

ResMed’s devices and software are subject to oversight by the U.S. Food and Drug Administration and analogous international regulatory bodies. Material regulatory actions (clearances, approvals, recalls, or safety communications) are disclosed in company filings and on regulators’ public databases.

For legal updates such as product‑related litigation or major compliance actions, material items typically appear in 8‑K filings or the company’s investor relations news releases.

Related securities and instruments

Investors and researchers may track related instruments:

• Options on RMD: for hedging, income or directional exposure if listed by exchanges.
• ETFs and mutual funds: many healthcare or medical device ETFs include ResMed as a component; tracking those funds provides sector exposure.
• ADRs / CDIs: CHESS Depositary Interests on the ASX provide an alternate route for Australian investors.
• Comparable companies: peers in the medical device and digital‑health space (device manufacturers, respiratory care firms, and digital health platforms) are useful for benchmarking valuation and operating metrics.

Historical resources and data sources

Primary sources for researching resmed stock include:

• Company investor relations: for earnings releases, presentations, and official statements.
• SEC filings: 10‑K, 10‑Q, 8‑K and proxy statements for authoritative financial and governance disclosures.
• Major market data providers and financial news portals for market metrics and historical price series.

These sources were the primary references used to structure this article. For live numbers always consult the original filings and up‑to‑date market feeds.

See also

• Sleep apnea market
• Medical device industry overview
• Cloud‑connected health and remote patient monitoring
• Dividend investing basics
• NYSE trading and market mechanics

References and external links

Below are examples of the types of sources you should consult to verify and extend the information in this guide. Do not treat the list below as exhaustive; always confirm with the primary documents.

• ResMed investor relations (official earnings releases and filings)
• SEC EDGAR filings (10‑K, 10‑Q, 8‑K)
• Major financial data providers and market portals for RMD market pages and historical data
• Financial news outlets for coverage of company events and analyst commentary

As of writing, specific metrics and reports mentioned above were reported by market data services and company releases. For example: As of 2024‑06‑30, according to major market data providers, resmed stock had a market capitalization reported in the low tens of billions USD and average daily volumes measured in the hundreds of thousands to low millions. These figures are time‑sensitive—always verify the latest numbers on the company IR page and quoted market data feeds.

Ready to follow resmed stock more closely? Use company filings and live market pages as your primary sources. For trading and custody, consider Bitget and Bitget Wallet for an integrated platform—check availability, fees and regulatory suitability for your jurisdiction. Explore the sections above to focus your next steps: market metrics, filings, and key risks are the best starting points for informed research.